Traws Pharma
Listed: NASDAQ: TRAWHas an LEI2 legal entities
Facts
as of Nov 17, 2026Targeting escape mutations in hematological cancers with first and best in class medicines.
- Legal name
- Traws Pharma, Inc.
- Headquarters
- Newtown, United States
- Employees
- 51-200estimated range
- Revenue
- $12018 · SEC Form D 0001104659-19-033519
- Legal entities
- 2 in 1 countries
- Listing
- NASDAQ: TRAW
- Register numbers
- NAME traws pharma inc
- Official records
- LEI 549300BRAR7BTG2PIY51SEC CIK 1130598
- Website
- trawspharma.com
These are the key facts about Traws Pharma on Alion as of Nov 17, 2026. Traws Pharma is headquartered in Newtown, United States. It has raised $15.8M in 3 funding rounds. The latest round is Venture - Series Unknown of $14M, announced in 2024.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Traws Pharma, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Newtown United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$1Revenue2018
$15.8MTotal raised
Venture - Series UnknownLatest round
3Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
Sources: funding announcements, grant and company registers
Milestones
Nov 5
New executive Iain Dukes, Executive Officer, Director · SEC Form D
Apr 1, 2024
Raised a round Venture round $14M · SEC Form D
May 10, 2019
Raised a round Venture round $500k · SEC Form D
Each milestone is dated by its source: registers, filings, the press
Newsroom
Aug 182026
News · Pulse 2.0
Traws Pharma has structured up to $50 million of potential additional financing around specific regulatory and clinical milestones for its influenza program, directly connecting…
May 82026
Press release · The Manila Times
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (
Apr 152026
Press release · The Manila Times
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Apr 22026
Press release · The Globe and Mail
Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.
Aug 8, 20252025
Press release · Nasdaq
--Traws Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today anno…
Jun 3, 20252025
Press release · The Globe and Mail
Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.
Sources: the outlets named on each headline, each story once
